Who Owns Atrium Therapeutics Stock?
NASDAQ: RNAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 65.86%
- Held by insiders
- 3.30%
- Institutional holders
- 200
- Institutions 65.9%
- Insiders 3.3%
- Public and other 30.8%
Who owns Atrium Therapeutics stock?
Institutional investors own about 65.9% of Atrium Therapeutics's shares, spread across 200 institutions that file 13F reports. That level of institutional ownership is moderate. Insiders, including executives, directors and large founding shareholders, hold 3.30% of RNA.
The largest institutional holders are Sessa Capital IM, L.P. (6.95%), Blackrock Inc. (5.65%) and Vanguard Capital Management LLC (3.38%). Together, the top 10 institutions control 32.2% of shares outstanding. In their latest filings, 3 of the top 10 institutions increased their RNA positions and 6 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of RNA
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Sessa Capital IM, L.P. | 1.50M | 6.95% | 0.0% |
| Blackrock Inc. | 1.22M | 5.65% | -15.8% |
| Vanguard Capital Management LLC | 730.03K | 3.38% | -0.1% |
| Price (T.Rowe) Associates Inc | 640.03K | 2.97% | -56.5% |
| O'Connor Alternative Investments LLC | 559.14K | 2.59% | -6.3% |
| Bracebridge Capital, LLC | 524.48K | 2.43% | +276.7% |
| TIG Advisors, LLC | 506.93K | 2.35% | -9.7% |
| Bank of America Corporation | 467.82K | 2.17% | +252.2% |
| Two Sigma Investments, LP | 427.38K | 1.98% | +23.7% |
| Geode Capital Management, LLC | 379.82K | 1.76% | -1.8% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of RNA
| Fund | Shares | % Held |
|---|---|---|
| T. Rowe Price Health Sciences Fund, Inc. | 566.43K | 2.63% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 518.42K | 2.40% |
| T. Rowe Price New Horizons Fund, Inc. | 443.26K | 2.05% |
| iShares Trust-iShares Russell 2000 ETF | 379.26K | 1.76% |
| TR PRICE-Price (T.Rowe) New Horizons Trust | 206.51K | 0.96% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 188.63K | 0.87% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 154.18K | 0.71% |
| NexPoint Funds I-NexPoint Merger Arbitrage Fund | 135.14K | 0.63% |
| iShares Trust-iShares Russell 2000 Growth ETF | 99.38K | 0.46% |
| VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | 82.34K | 0.38% |
Frequently asked questions
Who is the largest shareholder of Atrium Therapeutics?
Sessa Capital IM, L.P. is the largest institutional shareholder of RNA, owning 6.95% of shares outstanding (1.50M shares) as of its latest 13F filing.
What percentage of Atrium Therapeutics is owned by institutions?
Institutions own about 65.9% of RNA shares and 68.1% of the public float.
How much of Atrium Therapeutics do insiders own?
Insiders, such as officers and directors, own about 3.30% of RNA shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.